Free Trial

Lantern Pharma (LTRN) SEC Filings & 10K Form

Lantern Pharma logo
$3.38 +0.01 (+0.30%)
Closing price 06/11/2025 03:59 PM Eastern
Extended Trading
$3.38 0.00 (0.00%)
As of 08:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Recent Lantern Pharma SEC Filings

DateFilerForm TypeView
05/29/2025
8:53 PM
BP Directors, LP (Reporting)
Cavu Advisors, LLC (Reporting)
Cavu Management, LP (Reporting)
Kreis Leslie W. (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/29/2025
8:55 PM
BIOS Advisors GP, LLC (Reporting)
BIOS Capital Management, LP (Reporting)
Bios Equity Partners II, LP (Reporting)
Bios Equity Partners, LP (Reporting)
BIOS Fund I QP, LP (Reporting)
BIOS Fund I, LP (Reporting)
BIOS Fund II NT, LP (Reporting)
BIOS Fund II QP, LP (Reporting)
BIOS Fund II, LP (Reporting)
Fletcher Aaron G.L. (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
05/27/2025
7:55 PM
BIOS Fund I, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2025
7:56 PM
BIOS Fund II NT, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2025
7:58 PM
BIOS Fund I QP, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2025
8:00 PM
BIOS Fund II, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/27/2025
7:53 PM
BIOS Fund II QP, LP (Reporting)
Lantern Pharma (Subject)
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
05/15/2025
7:30 AM
Lantern Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
05/15/2025
7:35 AM
Lantern Pharma (Filer)
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
04/29/2025
7:56 PM
Lantern Pharma (Filer)
Form 10-K/A
11/07/2024
8:09 PM
Lantern Pharma (Filer)
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/26/2024
3:15 PM
KEYSER D JEFFREY (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Lantern Pharma (Issuer)
Silberstein David S. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Bhatia Kishor G. (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Chandru Vijay (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Lantern Pharma (Issuer)
Margrave David R. (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
KEYSER D JEFFREY (Reporting)
Lantern Pharma (Issuer)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Lantern Pharma (Issuer)
Maccecchini Maria-Luisa (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
07/17/2024
3:30 PM
Lantern Pharma (Issuer)
SHARMA PANNA (Reporting)
Form 4
Statement of changes in beneficial ownership of securities  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NASDAQ:LTRN) was last updated on 6/12/2025 by MarketBeat.com Staff
From Our Partners